[{"orgOrder":0,"company":"medac","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Syneos Health"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Pegylated Recombinant Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ PPD"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Dermatology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Eisai"},{"orgOrder":0,"company":"medac","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Dermatology","graph2":"Phase I","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"medac \/ PPD"},{"orgOrder":0,"company":"medac","sponsor":"IKP","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ IKP","highestDevelopmentStatusID":"7","companyTruncated":"medac \/ IKP"},{"orgOrder":0,"company":"medac","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"medac \/ UroGen Pharma","highestDevelopmentStatusID":"4","companyTruncated":"medac \/ UroGen Pharma"},{"orgOrder":0,"company":"medac","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ medac","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ medac"},{"orgOrder":0,"company":"medac","sponsor":"Celerion | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Celerion | Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Celerion | Syneos Health"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Syneos Health"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Celerion | Venn Life Sciences | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Celerion | Venn Life Sciences | Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Celerion | Venn Life Sciences | Syneos Health"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medac"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medac"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medac"},{"orgOrder":0,"company":"medac","sponsor":"Byondis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"DNA | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Medac","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Medac"},{"orgOrder":0,"company":"medac","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Stem Cell Transplant","moa":"Progenitor cell","graph1":"Oncology","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ medac","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ medac"},{"orgOrder":0,"company":"medac","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Fresenius Kabi","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Fresenius Kabi"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MC0518","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MC0518","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Glycostem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Medac","highestDevelopmentStatusID":"7","companyTruncated":"medac \/ Medac"},{"orgOrder":0,"company":"medac","sponsor":"Jakob Kristian Jakobsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Phase IV","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Jakob Kristian Jakobsen","highestDevelopmentStatusID":"11","companyTruncated":"medac \/ Jakob Kristian Jakobsen"},{"orgOrder":0,"company":"medac","sponsor":"Franco Locatelli","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Franco Locatelli","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Franco Locatelli"},{"orgOrder":0,"company":"medac","sponsor":"Prof. Dr. med. Wolfgang Bethge","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Prof. Dr. med. Wolfgang Bethge","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Prof. Dr. med. Wolfgang Bethge"}]
Find Clinical Drug Pipeline Developments & Deals by medac
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target